VISIPAQUE iodixanol 82.5g/150mL (550mg/mL) injection bag Australien - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 82.5g/150ml (550mg/ml) injection bag

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium chloride; calcium chloride dihydrate; trometamol; water for injections; sodium calcium edetate - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 82.5g/150mL (550mg/mL) injection bottle Australien - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 82.5g/150ml (550mg/ml) injection bottle

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 97.8g/150mL (652mg/mL) injection bag Australien - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 97.8g/150ml (652mg/ml) injection bag

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; sodium chloride; calcium chloride dihydrate; water for injections; trometamol; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

VISIPAQUE iodixanol 97.8g/150mL (652mg/mL) injection bottle Australien - engelsk - Department of Health (Therapeutic Goods Administration)

visipaque iodixanol 97.8g/150ml (652mg/ml) injection bottle

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; trometamol; calcium chloride dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid - visipaque is indicated, in adult patients, for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa).

0.9% SODIUM CHLORIDE INTRAVENOUS INFUSION BP 0.9% sodium chloride 50 mL intravenous infusion Australien - engelsk - Department of Health (Therapeutic Goods Administration)

0.9% sodium chloride intravenous infusion bp 0.9% sodium chloride 50 ml intravenous infusion

b braun australia pty ltd - sodium chloride, quantity: 0.45 g - injection, solution - excipient ingredients: water for injections - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established. 0.9% sodium chloride injection may also be used for irrigation of wounds and moistening of wound dressings. compound sodium lactate solution is particularly suitable for the replacement of extracellular fluid loss where isotonic dehydration is evident and in burn therapy.

ALBUMEX 4 albumin (human) 2g/50mL injection vial Australien - engelsk - Department of Health (Therapeutic Goods Administration)

albumex 4 albumin (human) 2g/50ml injection vial

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: chloride; octanoate; water for injections; sodium - indications as at 27 january 2000 :hypovolaemia/shock: preservation of an adequate cirulating blood volume should be the primary aim of therapy. the initial resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre) or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, aneamia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

ALBUMEX 4 albumin (human) 10g/250mL injection     vial Australien - engelsk - Department of Health (Therapeutic Goods Administration)

albumex 4 albumin (human) 10g/250ml injection vial

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: chloride; water for injections; sodium; octanoate - indications as at 27 january 2000 : hypovolaemia/shock: preservation of an adequate circulating blood volume should be the primary aim of therapy. the initial resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre), or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, anaemia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be a preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

TIROFIBAN JUNO tirofiban (as hydrochloride) 12.5mg/50mL Concentrated Injection for infusion Vial Australien - engelsk - Department of Health (Therapeutic Goods Administration)

tirofiban juno tirofiban (as hydrochloride) 12.5mg/50ml concentrated injection for infusion vial

juno pharmaceuticals pty ltd - tirofiban hydrochloride, quantity: 14.05 mg (equivalent: tirofiban, qty 12.5 mg) - injection, concentrated - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid; dibasic sodium phosphate dihydrate; water for injections - tirofiban juno, in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischaemic events. (see pharmacology and dosage and administration.)

NIMOTOP 10mg/50mL injection vial Australien - engelsk - Department of Health (Therapeutic Goods Administration)

nimotop 10mg/50ml injection vial

bayer australia ltd - nimodipine, quantity: 0.2 mg/ml - injection, intravenous infusion - excipient ingredients: ethanol; macrogol 400; sodium citrate dihydrate; citric acid; water for injections - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus (eg hunt and hess grades i-iii).